The Medication Shield is Synapse Platform’s artificial intelligence solution for pharmacovigilance that facilitates the management of adverse event reports.
Synapse Medicine’s Medication Shield technology was awarded the 2021 Prix Galien, France in the digital health category, and was recently nominated for the 2022 Prix Galien International.
The Medication Shield identifies in real-time the drugs involved by coding them in ATC class.
Using NLP algorithms, the Medication Shield detects adverse events by coding them in MedDRA terminology.
It analyzes the seriousness level of adverse events to enable their classification and increases pharmacovigilance teams’ reactivity.
Finally, it determines the expected or unexpected nature of the ADE and its frequency of occurrence according to the drug monograph.
The "Medication Shield" technology manages adverse drug reaction (ADR) signals in real-time by encoding them automatically into a standardized, international terminology (MedDRA) and ranking them by severity. This helps pharmacovigilance teams in their daily management of ADRs reports.
The Medication Shield's natural language processing (NLP) algorithms extract the terms used when reporting an adverse reaction and find their corresponding term according to MedDRA classification. The Medication Shield then analyzes whether the adverse reaction is expected, its level of severity and its frequency.
The Medication Shield integrates easily with third-party ADE management software. It allows actors involved in pharmacovigilance to benefit from the power of the Medication Shield’s artificial intelligence while continuing to use their everyday software.
The Medication Shield is also being used as part of the COVID-19 vaccination campaign in France. In partnership with the ANSM*, the integration of the Medication Shield facilitates the daily management of adverse event reports by pharmacovigilance teams.
*Agence Nationale de Sécurité du Médicament et des produits de santé
The reporting portal implemented by the French Ministry of Health allows the Regional Pharmacovigilance Centers (CRPVs) to be notified of ADRs detected by healthcare professionals (HCP), patients, or by the pharmaceutical industry.
Synapse Medicine uses its Medication Intelligence technology expertise to help Regional Pharmacovigilance Centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM) to manage ADR reports. The "Medication Shield" technology encodes ADR signals according to an international terminology (MedDRA) and ranks them by severity.
Regional Pharmacovigilance Centers can thereby benefit from an easier and faster reading of data linked to ADR reports. Synapses' technology is a valuable time-saver that allows them to focus their attention on the most complex cases.
The Medication Shield simplifies ADR signals processing and allows health authorities to detect them faster after the drug is commercialized.
Our latest publication on the "Medication Shield" technology, Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions can be found in the August 2021 issue of Clinical Pharmacology & Therapeutics, a leading international scientific journal.
Synapse Medicine, the ANSM (French equivalent to the FDA), the Pharmacology Department of Bordeaux University Hospital, and the Pharmacoepi - Inserm U1219 BPH team of the University of Bordeaux.
Learn how your organization can benefit from our Medication Success technology